In relation to osteoprotegerin (OPG), pre-clinical studies indicate that it reduces pain behavior development and joint pathology in a model of osteoarthritis [492], and alleviates pain in rats subjected to bone cancer [493,494]. This evidence concerns the gene TNFRSF11B and bone cancer.